Evidence map›Paper›PMID 35533978›Full record

ArticleContemporary clinical trials2022

Implementing expanded COVID-19 testing in Massachusetts community health centers through community partnerships: Protocol for an interrupted time series and stepped wedge study design.

Gina R Kruse, Leslie Pelton-Cairns, Elsie M Taveras, Susan Dargon-Hart, Daniel A Gundersen, Rebekka M Lee, Barbara E Bierer, Erica Lawlor, Regina C LaRocque, Julia L Marcus and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Contemporary clinical trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Gina R KruseMassachusetts General Hospital, Division of General Internal Medicine, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02114, USA. Electronic address: gkruse@mgh.harvard.edu.
Leslie Pelton-CairnsMassachusetts League of Community Health Centers, Boston, MA 02114, USA.
Elsie M TaverasHarvard Medical School, Boston, MA 02114, USA; Massachusetts General Hospital, Kraft Center for Community Health, Boston, MA 02114, USA; Massachusetts General Hospital, Division of Academic Pediatrics, Boston, MA 02114, USA.
Susan Dargon-HartMassachusetts League of Community Health Centers, Boston, MA 02114, USA.
Daniel A GundersenDana Farber Cancer Institute, Division of Population Sciences, Boston, MA, USA.
Rebekka M LeeHarvard T.H. Chan School of Public Health, Department of Social and Behavioral Sciences, Boston, MA, USA; Harvard Catalyst | The Harvard Clinical and Translational Science Center, Boston, MA, USA.
Barbara E BiererHarvard Medical School, Boston, MA 02114, USA; Harvard Catalyst | The Harvard Clinical and Translational Science Center, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA.
Erica LawlorHarvard Medical School, Boston, MA 02114, USA; Harvard Catalyst | The Harvard Clinical and Translational Science Center, Boston, MA, USA.
Regina C LaRocqueHarvard Medical School, Boston, MA 02114, USA; Massachusetts General Hospital, Division of Infectious Diseases, Boston, MA 02114, USA.
Julia L MarcusDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.
Madeline E DaviesMassachusetts General Hospital, Kraft Center for Community Health, Boston, MA 02114, USA.
Karen M EmmonsHarvard T.H. Chan School of Public Health, Department of Social and Behavioral Sciences, Boston, MA, USA; Harvard Catalyst | The Harvard Clinical and Translational Science Center, Boston, MA, USA.
RADx-MA Partnership
Harvard University · USCommunity Health Center · USMassachusetts General Hospital · USCommunity Catalyst · USDana-Farber Cancer Institute · US

Funding

The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
U Mass Boston / DFHCC U54 Partnership (1 of 2)U54CA156732 · NCI · DANA-FARBER CANCER INST · PI Shoba Ramanadhan · 2010 to 2026
$25.6M
The Implementation Science Center for Cancer Control Equity - Research ProgramP50CA244433 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI EMMONS, KAREN M. · 2019 to 2023
$12.5M
Patient Oriented Research and Mentorship in Childhood Obesity DisparitiesK24HL159680 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI TAVERAS BENAVIDEZ, ELSIE MIREYA · 2021 to 2025
$510k
NCATS NIH HHS UL1 TR002541NCI NIH HHS P50 CA244433NCI NIH HHS U54 CA156732NHLBI NIH HHS K24 HL159680
6 · The paper itself

Abstract

backgroundCommunity Health Centers (CHCs) are a critical source of care for low-income and non-privately insured populations. During the pandemic, CHCs have leveraged their infrastructure and role as a trusted source of care to engage the communities they serve in COVID-19 testing.

methodsTo directly address the impact that COVID-19 has had on historically marginalized populations in Massachusetts, we designed a study of community-engaged COVID-19 testing expansion: (1) leveraging existing partnerships to accelerate COVID-19 testing and rapidly disseminate effective implementation strategies; (2) incorporating efforts to address key barriers to testing participation in communities at increased risk for COVID-19; (3) further developing partnerships between communities and CHCs to address testing access and disparities; (4) grounding the study in the development of a shared ethical framework for advancing equity in situations of scarcity; and (5) developing mechanisms for communication and science translation to support community outreach. We use a controlled interrupted time series design, comparing number of COVID-19 tests overall and among people identified as members of high-risk groups served by intervention CHCs compared with six matched control CHCs in Massachusetts, followed by a stepped wedge design to pilot test strategies for tailored outreach by CHCs.

conclusionsHere, we describe a community-partnered strategy to accelerate COVID-19 testing in historically marginalized populations that provides ongoing resources to CHCs for addressing testing needs in their communities. The study aligns with principles of community-engaged research including shared leadership, adequate resources for community partners, and the flexibility to respond to changing needs over time.

Indexed as

COVID-19COVID-19 TestingCommunity Health CentersHumansInterrupted Time Series AnalysisMassachusettsCommunity-engaged researchCommunity health centersCOVID-19 testingHealth equityImplementation science

Identifiers

PMID35533978
PMCPMC9076025
OpenAlexW4228998114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.